Upon joining the study, you will attend an initial visit. During this visit, your eligibility for the trial will be confirmed based on specific criteria, such as age and the extent of your plaque psoriasis.

You will be informed about the trial’s procedures, and any questions you have will be addressed. Consent will be obtained to ensure you understand and agree to participate.

After the initial visit, you will be randomly assigned to one of the treatment groups. This means you may receive either the new medication ESK-001, a placebo, or an active comparator like Otezla (apremilast).

The assignment is random to ensure fairness and objectivity in the study results.

During the treatment phase, you will take the assigned medication orally. If you are in the ESK-001 group, you will take the medication as a tablet. If you are in the Otezla group, you will take either 10 mg, 20 mg, or 30 mg film-coated tablets.

The treatment will last for up to 16 weeks. You will be required to take the medication as directed by the study team, which will provide specific instructions on dosage and frequency.

Throughout the trial, you will attend regular follow-up visits. These visits are important for monitoring your health and the effects of the treatment.

During these visits, various assessments will be conducted, including physical examinations and questionnaires about your condition and quality of life.

At the end of the 16-week treatment period, a final evaluation will be conducted. This will include assessments similar to those during the follow-up visits.

The purpose of this evaluation is to determine the effectiveness and safety of the treatment you received.